Compugen Targets 2027 Milestone as Cash Runway Extends to 2029

The MAIA-ovarian trial, a randomized platform study evaluating COM701 as a maintenance monotherapy for relapsed platinum-sensitive ovarian cancer, remains the central pillar of the company's development efforts. CEO Eran Ophir noted that the trial aims to address a significant unmet need in a patient population currently lacking approved treatment options. Recent data presented at the ESMO Gynaecological Cancers Congress in Copenhagen highlighted the distinct biological rationale for targeting the PVRIG pathway, reinforcing the potential for COM701 to serve as a backbone for future drug combinations.

Beyond its proprietary pipeline, Compugen continues to see progress in its partnered programs. AstraZeneca reported an updated median overall survival of 16.8 months for rilvegostomig in the GEMINI-Hepatobiliary study, marking the first survival readout for the PD-1/TIGIT bispecific antibody. Meanwhile, the Phase 1 trial for GS-0321, a novel anti-IL-18 binding protein antibody licensed to Gilead, is advancing according to schedule.

Financially, the company reported a net loss of approximately $7.0 million for the second quarter of 2026, an improvement over the $7.3 million loss during the same period in 2025. With $125.3 million in cash and cash-related assets as of June 30, 2026, and no debt, management maintains that the company is well-capitalized to sustain its ongoing research and clinical development through 2029.